AU682335B2 - Monoclonal antibodies and anti-idiotypic antibodies to hepatitis C virus - Google Patents
Monoclonal antibodies and anti-idiotypic antibodies to hepatitis C virusInfo
- Publication number
- AU682335B2 AU682335B2 AU58346/94A AU5834694A AU682335B2 AU 682335 B2 AU682335 B2 AU 682335B2 AU 58346/94 A AU58346/94 A AU 58346/94A AU 5834694 A AU5834694 A AU 5834694A AU 682335 B2 AU682335 B2 AU 682335B2
- Authority
- AU
- Australia
- Prior art keywords
- antibodies
- under deposit
- cell line
- idiotypic
- monoclonal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000711549 Hepacivirus C Species 0.000 title claims description 40
- 210000004027 cell Anatomy 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 13
- 210000004102 animal cell Anatomy 0.000 claims description 12
- 238000004113 cell culture Methods 0.000 claims description 12
- 230000027455 binding Effects 0.000 claims description 11
- 230000003248 secreting effect Effects 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 210000004408 hybridoma Anatomy 0.000 claims description 7
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- 238000003149 assay kit Methods 0.000 claims description 2
- 238000003556 assay Methods 0.000 description 20
- 210000003719 b-lymphocyte Anatomy 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 10
- 108700023195 montirelin Proteins 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 7
- 208000006454 hepatitis Diseases 0.000 description 7
- 231100000283 hepatitis Toxicity 0.000 description 7
- 239000008279 sol Substances 0.000 description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 2
- 241000724709 Hepatitis delta virus Species 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 101100210013 Maize stripe virus NS-5 gene Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002736 metal compounds Chemical class 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 101710088758 23kDa protein Proteins 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- XDVMCVGTDUKDHL-UHFFFAOYSA-N [amino(2-azaniumylethylsulfanyl)methylidene]azanium;dibromide Chemical compound Br.Br.NCCSC(N)=N XDVMCVGTDUKDHL-UHFFFAOYSA-N 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
- C07K16/109—Hepatitis C virus; Hepatitis G virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP92204107 | 1992-12-29 | ||
| EP92204107 | 1992-12-29 | ||
| PCT/EP1993/003707 WO1994014974A1 (en) | 1992-12-29 | 1993-12-27 | Monoclonal antibodies and anti-idiotypic antibodies to hepatitis c virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU5834694A AU5834694A (en) | 1994-07-19 |
| AU682335B2 true AU682335B2 (en) | 1997-10-02 |
Family
ID=8211185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU58346/94A Expired - Fee Related AU682335B2 (en) | 1992-12-29 | 1993-12-27 | Monoclonal antibodies and anti-idiotypic antibodies to hepatitis C virus |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0628084A1 (de) |
| JP (1) | JPH07504333A (de) |
| KR (1) | KR950700423A (de) |
| AU (1) | AU682335B2 (de) |
| CA (1) | CA2127797A1 (de) |
| FI (1) | FI943524A (de) |
| WO (1) | WO1994014974A1 (de) |
| ZA (1) | ZA939756B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6822563B2 (en) | 1997-09-22 | 2004-11-23 | Donnelly Corporation | Vehicle imaging system with accessory control |
| JP3217600B2 (ja) * | 1994-07-12 | 2001-10-09 | 株式会社先端生命科学研究所 | 非ａ非ｂ型肝炎ウイルス関連抗原のイムノアッセイ、それに使用するモノクローナル抗体、およびこの抗体を産生するハイブリドーマ |
| JP2002171972A (ja) * | 1996-10-14 | 2002-06-18 | Chemo Sero Therapeut Res Inst | 肝炎ウイルスエピトープ |
| DE10112748A1 (de) * | 2001-03-14 | 2002-09-19 | Transmit Technologietransfer | Erfindung betreffend HCV-Erkrankungen |
| WO2002082089A2 (en) * | 2001-04-03 | 2002-10-17 | Immune Network Ltd. | Anti-idiotypic antibody and its use in diagnosis and therapy of hepatitis c virus related diseases |
| ES2391556T3 (es) | 2002-05-03 | 2012-11-27 | Donnelly Corporation | Sistema de detección de objetos para vehículo |
| US7526103B2 (en) | 2004-04-15 | 2009-04-28 | Donnelly Corporation | Imaging system for vehicle |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4046489A (en) * | 1988-07-06 | 1990-02-05 | Genelabs Incorporated | Post-transfusion, non-a, non-b hepatitis virus and antigens |
-
1993
- 1993-12-27 WO PCT/EP1993/003707 patent/WO1994014974A1/en not_active Application Discontinuation
- 1993-12-27 KR KR1019940703025A patent/KR950700423A/ko not_active Application Discontinuation
- 1993-12-27 CA CA002127797A patent/CA2127797A1/en not_active Abandoned
- 1993-12-27 JP JP6507580A patent/JPH07504333A/ja active Pending
- 1993-12-27 AU AU58346/94A patent/AU682335B2/en not_active Expired - Fee Related
- 1993-12-27 EP EP94904191A patent/EP0628084A1/de not_active Withdrawn
- 1993-12-29 ZA ZA939756A patent/ZA939756B/xx unknown
-
1994
- 1994-07-27 FI FI943524A patent/FI943524A/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0628084A1 (de) | 1994-12-14 |
| WO1994014974A1 (en) | 1994-07-07 |
| JPH07504333A (ja) | 1995-05-18 |
| CA2127797A1 (en) | 1994-07-07 |
| AU5834694A (en) | 1994-07-19 |
| ZA939756B (en) | 1994-08-18 |
| FI943524A0 (fi) | 1994-07-27 |
| FI943524A (fi) | 1994-07-27 |
| KR950700423A (ko) | 1995-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Meunier et al. | Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus | |
| US8007792B2 (en) | Antibodies directed against hepatitis C virus E1E2 complex, compositions of HCV particles, and pharmaceutical compositions | |
| Burioni et al. | Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments | |
| EP1097172A1 (de) | Anti-hepatitis c virus antikörper und verwendung davon | |
| Mondelli et al. | Antibody responses to hepatitis C virus hypervariable region 1: evidence for cross‐reactivity and immune‐mediated sequence variation | |
| Cerino et al. | Identification of an immunodominant B cell epitope on the hepatitis C virus nonstructural region defined by human monoclonal antibodies. | |
| AU682335B2 (en) | Monoclonal antibodies and anti-idiotypic antibodies to hepatitis C virus | |
| US5753430A (en) | Monoclonal antibodies to hepatitis C virus and method for using same | |
| FI105275B (fi) | Hepatiitti C-viruksen vastaisia monoklonaalisia vasta-aineita | |
| KR100491139B1 (ko) | 씨형 간염 바이러스의 이투 당단백질에 대한 인간의 모노클로날 항체 | |
| AU662503B2 (en) | Monoclonal antibodies to hepatitis C virus and method for using same | |
| US6541198B1 (en) | Antibodies and other binding molecules specific for hepatitis B viral antigens | |
| US5670310A (en) | Methods and compositions for differential diagnosis of acute and chronic hepatitis c virus infection | |
| WO1994013699A1 (en) | Hepatitis c virus (hcv) non-structural-3 peptides, antibodies thereto and methods for the detection of hcv | |
| Baumert et al. | Inhibition of Hepatitis C Virus-Like Particle |